Enliven reports Q4/FY2025 results; initial Phase 1b data for ELVN-001 shows MMR rates 47-69%

Enliven Therapeutics, Inc.

Net loss of $29.7M for Q4 2025 vs $23.2M for Q4 2024; full year net loss $103.7M vs $89.0M.
Cash, equivalents and marketable securities $462.6M, providing runway into first half of 2029.
Initial Phase 1b data: MMR achieved in 47% (80 mg QD) and 69% (60/120 mg QD) of evaluable patients.
Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected to initiate in second half of 2026.
Rick Fair appointed CEO in December 2025; Scott Garland added to board in January 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.